← SynDRA
ABAMETAPIR
SynDRA canonical compound SYN0034310 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
| Approval status | Approved · OTC |
| Primary target(s) | MMP2 | MMP8 | MMP9 |
| Mechanism of action | metalloproteinase inhibitor |
All known targets
- CCR1
- CCR5
- CCR8
- MMP2
- MMP8
- MMP9
Mechanisms of action (all sources)
- metalloproteinase inhibitor
ATC classes
- P03A · ECTOPARASITICIDES, INCL. SCABICIDES
Cross-references
Synonyms
- xeglyze
- Ha44
- 5,5'-dimethyl-2,2'-dipyridyl
- 6,6'-bi-3-picoline
- HA-44
- Xeglyze
- 5,5'-Dimethyl-2,2'-bipyridine
- 5,5'-Dimethyl-2,2'-dipyridyl
- 5,5'-Dimethyl-2,2'-bipyridyl
- 6,6'-Bi-3-picoline
- 2,2'-BIPYRIDINE, 5,5'-DIMETHYL-
- 6,6'-Di-3-picolyl
- 6,6'-Di-3-picoline
- UNII-6UO390AMFB
- 5-methyl-2-(5-methylpyridin-2-yl)pyridine
- MFCD01740554
- 6UO390AMFB
- CHEMBL2205807
- 5,5'-dimethyl-2,2'-bipyridinyl
- 5,5 -Dimethyl-2,2 -bipyridine
- BRN 0123183
- Abametapir [USAN:INN]
- Xeglyze(Abametapir)
- Xeglyze (TN)
- PubChem24353
- Abametapir (USAN/INN)
- ACMC-209eb4
- SCHEMBL351152
- HA44
- 2,2 -Bis-(5-methylpyridyl)
- DTXSID00170095
- ZINC403335
- 9238AA
- ANW-22814
- BDBM50401351
- LT0042
- s5752
- 5,5''-Dimethyl-2,2''-bipyridine
Reported adverse events
- Erythema
- Eye irritation
- Rash
- Vomiting
- Skin burning sensation
Look up ABAMETAPIR in the interactive SynDRA portal →